Determination of the optimal echocardiographic scoring system to quantify carcinoid heart disease.
Affiliation
Neuroendocrine Tumour Group, University of Liverpool, Liverpool, UK.Issue Date
2014
Metadata
Show full item recordAbstract
Carcinoid heart disease (CHD) is an important complication of metastatic neuroendocrine disease, requiring regular monitoring to enable intervention prior to right heart failure. We aimed to identify the most appropriate echocardiographic scoring systems for the quantitative assessment of CHD.Citation
Determination of the optimal echocardiographic scoring system to quantify carcinoid heart disease. 2014, 99 (2):85-93 NeuroendocrinologyJournal
NeuroendocrinologyDOI
10.1159/000360767PubMed ID
24603343Type
ArticleLanguage
enISSN
1423-0194ae974a485f413a2113503eed53cd6c53
10.1159/000360767
Scopus Count
Collections
Related articles
- Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease.
- Authors: Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J
- Issue date: 2008 Oct 1
- Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.
- Authors: Korse CM, Taal BG, de Groot CA, Bakker RH, Bonfrer JM
- Issue date: 2009 Sep 10
- The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study.
- Authors: Dobson R, Burgess MI, Banks M, Pritchard DM, Vora J, Valle JW, Wong C, Chadwick C, George K, Keevil B, Adaway J, Ardill JE, Anthoney A, Hofmann U, Poston GJ, Cuthbertson DJ
- Issue date: 2013
- Variation in Cardiac Screening and Management of Carcinoid Heart Disease in the UK and Republic of Ireland.
- Authors: Dobson R, Valle JW, Burgess MI, Poston GJ, Cuthbertson DJ
- Issue date: 2015 Dec
- Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease.
- Authors: Zuetenhorst JM, Korse CM, Bonfrer JM, Bakker RH, Taal BG
- Issue date: 2004 Jun 1